pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

FDA 52

FDA 52

pharmaphorum

SEPTEMBER 15, 2020

The huge rise in the use of telemedicine services during lockdown has brought care directly to patients in their homes, while pharma’s communications with healthcare professionals (HCPs) has experienced a similar push to digital channels. Jeremy Richter, Tag. We’re all trying to find ways to automate. About the interviewees.

Communication 118

Communication Documentation Labelling Vaccines 118

pharmaphorum

JUNE 8, 2021

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. ICER points to brain swelling and potential bleeding seen in approximately 30% of patients treated with aducanumab. Broad label questioned.

FDA 98

FDA Labelling 98

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Virtual connections. Engagement channels. Regulated industry learnings.

Communication 91

Communication Insurance Packaging Pharmaceutical Companies 91

pharmaphorum

JANUARY 31, 2023

This lack of trust in such a crucial industry can lead to decreased compliance, poor treatment adherence, and negative health outcomes for patients. Additionally, when patients are prescribed medication, they are often unaware of the mechanism of action, potential side effects, interactions, and contraindications.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines Communication 52

pharmaphorum

OCTOBER 29, 2021

Trodelvy has already established itself as a go-to therapy for TNBC patients whose disease has progressed after prior treatments, says Gilead, while Keytruda is approved as a first-line therapy for the cancer in combination with chemotherapy, in patients with PD-L1 scores of 10 or more. While its headline revenue of $7.4

Chemotherapy 52

Chemotherapy FDA 52

PharmD Live

DECEMBER 21, 2021

Virtual care, normalized by the pandemic, is now common practice for providers and patients, especially at the primary care level–a boon in 2021 for underserved chronic care populations. Aduhelm was approved by the FDA in 2021 with clinical trials outcome data indicating the potential to slow the accumulation of amyloid plaques.

FDA 52

FDA Hospitals 52

pharmaphorum

JANUARY 5, 2021

The FDA’s breakthrough status is for tiragolumab plus Tecentriq is the first for a TIGIT drug, and covers the first-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC) that expresses high levels of PD-L1. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Chemotherapy 52

Chemotherapy Immunization FDA Labelling 52

PharmD Live

JANUARY 25, 2022

With the challenging number of diagnoses and medications that Medicare patients take, it is essential to have a team member whose primary function is to rapidly review patients records, give informed advice on any side effects to watch out for, and give medication interaction alerts to the rest of the care team.

Adverse Reactions 52

Adverse Reactions Patient Care Communication Hospitals 52

pharmaphorum

JUNE 2, 2021

NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA UK. The post NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group appeared first on.

Documentation 52

Documentation Communication 52

pharmaphorum

MAY 10, 2022

The FDA awarded a fast-track designation to lecanemab in December and has also given the drug breakthrough tag as a treatment for early-stage Alzheimer’s, and Biogen and Eisai will be hoping the drug can sidestep the controversy that engulfed Aduhelm from the moment it was approved.

FDA 40

FDA 40

European Pharmaceutical Review

AUGUST 24, 2022

there are 14 approved ADCs on the global market, all for oncology indications, and over 140 ADCs currently in clinical development” More than 20 years ago, the first ADC, Mylotarg, was approved for use in patients with relapsed or refractory acute myeloid leukaemia (AML). The culmination of two decades of learning.

Compounding 84

Compounding Pharmaceutical Companies Pharmaceutical Companies 84

pharmaphorum

JUNE 2, 2022

When asked by pharmaphorum why product sales are expected to be so high in this area, a spokesperson for Evaluate explained: “For many rare diseases, there is high unmet need which results in high levels of use of orphan products in the eligible patient groups, and these groups are often larger than anticipated once treatments become available.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Colors Make me Happy

AUGUST 19, 2020

For example, Fatima, along with tens of thousands of Kurdish refugees, were assigned the same birthdate (July 1) regardless of their real day of birth, which naturally causes issues in determining a patient’s actual age. Also, just because a refugee patient is now in a safer place, it doesn’t mean they are not terribly frightened.

Compounding 40

Compounding Communication 40

pharmaphorum

NOVEMBER 16, 2022

The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in smaller patient populations. Advanced therapies have changed the treatment landscape for the industry and for patients. However, with a price tag of €1.58

131

131

The Checkup by Singlecare

SEPTEMBER 7, 2023

Still, more recently, Glucagon-like peptide-1 receptor agonists (GLP-1-RA) have become the first-line treatment for those patients with established atherosclerotic coronary vascular disease (ASCVD). Some patients may experience an injection site reaction that is bothersome. Mounjaro (tirzepaptide), manufactured by Eli Lilly Inc.,

Insurance 52

Insurance Insurance Coverage FDA Dosage 52

Pharmaceutical Technology

JANUARY 27, 2023

Before Cablivi’s approval, patients relied on a combination of plasma exchange plus corticosteroids and immunomodulators as the standard of care (SOC) for treatment. Sanofi’s eligibility requirements follow a similar model to Pfizer’s previous programs, with refunds being dependent on lack of clinical outcome in patients.

Documentation 52

Documentation Immunization Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

AUGUST 26, 2022

million for the one-shot therapy – in other words, after any discounts that it may offer or outcomes-based agreements – aiming to launch first in Germany followed by France. BioMarin has said Roctavian will be available at a ‘net’ price of around €1.5 million spread over five years.

FDA 111

FDA 111

pharmaphorum

JUNE 15, 2021

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. New Science is more important than ever. So we know change is not impossible.

Vaccines 90

Vaccines 90

pharmaphorum

OCTOBER 4, 2022

A key part of this initiative was the establishment of the Cancer Moonshot Biobank, which will ask cancer patients to donate biospecimens and associated health information to aid research. The objective is to gather patient biospecimens longitudinally to understand how patients react to treatments and how cancer develops over time.

Documentation 104

Documentation Data Entry HIPAA Insurance 104

The Checkup by Singlecare

JUNE 21, 2023

The condition causes higher levels of androgen hormone production, resulting in symptoms such as irregular menstrual cycles, acne, excess hair growth, cysts, skin tags, thinning hair, skin darkening, and infertility. Sood expects them to show a positive outcome of this class of drugs as a whole. Related: What is PCOS?

Insurance 98

Insurance FDA Compounding Compounding Pharmacies 98

European Pharmaceutical Review

DECEMBER 27, 2023

Due to shipping and manufacturing requirements, the time from a patient being included in the CAR T programme to receiving therapy can be several weeks. As a result, many patients waiting for the CAR T cells to be infused will need additional therapy (bridging therapy) against the malignance.

Adverse Reactions 85

Adverse Reactions Immunization Medical Schools Chemotherapy 85

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.

Health and Personal Care Stores 40

Health and Personal Care Stores Hospitals Mayo Clinic Specialty Pharmacies 40